bioAffinity Technologies Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

bioAffinity Technologies heeft een totaal eigen vermogen van $3.8M en een totale schuld van $59.0K, wat de schuld-eigenvermogensverhouding op 1.6% brengt. De totale activa en totale passiva bedragen respectievelijk $7.6M en $3.9M.

Belangrijke informatie

1.57%

Verhouding schuld/eigen vermogen

US$59.03k

Schuld

Rente dekkingsratio	n/a
Contant	US$2.43m
Aandelen	US$3.77m
Totaal verplichtingen	US$3.85m
Totaal activa	US$7.62m

Recente financiële gezondheidsupdates

Analyse-artikel • Mar 05

Here's Why bioAffinity Technologies (NASDAQ:BIAF) Must Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Recent updates

Analyse-artikel • Mar 05

Here's Why bioAffinity Technologies (NASDAQ:BIAF) Must Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Seeking Alpha • Sep 28

bioAffinity Technologies receives ~$7.7M from exercise of warrants

bioAffinity Technologies (NASDAQ:BIAF) received ~$7.7M from the exercise of its tradeable and non-tradable warrants issued as part of the Sep. 6 public offering of securities. A total of 725,576 tradeable warrants at $7.35 per share and 310,910 non-tradable warrants at $7.656 per share were exercised. Separately, the company had received ~$7.9M in gross proceeds from the underwritten public offering of 1,282,600 units. The proceeds are intended to be used to expand existing operations, for the commercialization of its CyPath Lung test and regulatory approvals and research and development of additional diagnostics and cancer therapeutics. It may also be used for working capital and general corporate purposes. Shares were trading +52.36% pre-market. Source: Press Release

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( $3.9M ) BIAF } overtreffen de korte termijn passiva ( $2.7M ).

Langlopende schulden: De kortetermijnactiva BIAF ( $3.9M ) overtreffen de langetermijnschulden ( $1.2M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: BIAF heeft meer geld in kas dan de totale schuld.

Schuld verminderen: BIAF had 5 jaar geleden een negatief eigen vermogen, maar is nu positief en is dus verbeterd.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: BIAF heeft voldoende cash runway voor 3 maanden op basis van de laatst gerapporteerde vrije kasstroom, maar heeft sindsdien extra kapitaal opgehaald.

Voorspelling contante baan: Er wordt voorspeld dat BIAF voldoende kasmiddelen zal hebben voor 2 maanden op basis van de vrije kasstroom schattingen, maar heeft sindsdien extra kapitaal opgehaald.

Ontdek gezonde bedrijven

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2026/09/11 09:22
Aandelenkoers aan het einde van de dag	2026/09/11 00:00
Inkomsten	2026/06/30
Jaarlijkse inkomsten	2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

bioAffinity Technologies, Inc. wordt gevolgd door 1 analisten. 0 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Anthony Vendetti	Maxim Group

bioAffinity Technologies Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Bioaffinity Technologies, Inc. Receives Notice of Non-Compliance with Minimum Bid Price Requirement from Nasdaq Stock Market LLC

bioAffinity Technologies Receives Non-Compliance Letter from Nasdaq Regarding Minimum Stockholders' Equity Requirement

bioAffinity Technologies Receives Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price Requirement

Here's Why bioAffinity Technologies (NASDAQ:BIAF) Must Use Its Cash Wisely

Recent updates

BioAffinity Technologies Advances CyPath Lung for Surveillance of Lung Cancer Survivors

New major risk - Share price stability

Second quarter 2026 earnings released: US$0.64 loss per share (vs US$5.07 loss in 2Q 2025)

Bioaffinity Technologies, Inc. Receives Notice of Non-Compliance with Minimum Bid Price Requirement from Nasdaq Stock Market LLC

High number of new and inexperienced directors

bioAffinity Technologies Reports Positive Preclinical Findings for Proprietary Gene Silencing Technology Targeting Squamous and Basal Skin Cancer Cells

bioAffinity Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $3.2 million.

bioAffinity Technologies, Inc. has filed a Follow-on Equity Offering in the amount of $4 million.

First quarter 2026 earnings released: US$0.81 loss per share (vs US$4.91 loss in 1Q 2025)

New major risk - Market cap size

bioAffinity Technologies, Inc. Releases Clinical Case Study Demonstrating Cypath Lung Diagnostic Test Performance

bioAffinity Technologies, Inc. Releases New Clinical Case Study That Highlights the Benefit of Adding CyPath Lung

Full year 2025 earnings released: US$8.66 loss per share (vs US$22.37 loss in FY 2024)

Bioaffinity Technologies Initiates Large-Scale Longitudinal Clinical Study for Noninvasive Cypath Lung Cancer Diagnostic

bioAffinity Technologies, Inc. Presents Positive Research Findings for Its Novel Diagnostic Platform Technology to Identify Optimal Therapies for Asthma Patients

bioAffinity Technologies, Inc. Announces Validation Study with Brooke Army Medical Center to Expand Sample Collection

New major risk - Share price stability

bioAffinity Technologies, Inc. Releases New Clinical Study Results

bioAffinity Technologies, Inc. Announces New Clinical Case Study Demonstrating How CyPath Lung

bioAffinity Technologies, Inc. Announces Medical and Scientific Advisory Board Appointments

bioAffinity Technologies, Inc., Annual General Meeting, Apr 30, 2026

New major risk - Revenue and earnings growth

New major risk - Financial position

Third quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

bioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer

bioAffinity Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $1.8 million.

bioAffinity Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $4.798284 million.

bioAffinity Technologies, Inc. Releases Three Additional Case Studies

bioAffinity Technologies, Inc. has filed a Follow-on Equity Offering in the amount of $4 million.

bioAffinity Technologies, Inc. Releases Another Completes a Completion of CyPath®? Lung, Identifies Cancer in a Patient with an Intention of Ground-Glass Lung Nodules

Less than half of directors are independent

bioAffinity Technologies, Inc. Announces Board Changes

New major risk - Negative shareholders equity

Second quarter 2025 earnings: EPS and revenues miss analyst expectations

bioAffinity Technologies, Inc. announced that it has received $0.99 million in funding

bioAffinity Technologies, Inc. announced that it expects to receive $0.99 million in funding

bioAffinity Technologies, Inc. Announces CyPath®? Lung Detects Stage 1A Lung Cancer in High-Risk Patient with Inconclusive Imaging and Low-Risk Serum Test Results

bioAffinity Technologies, Inc. Releases A Compelling New Case Study in Which CyPath® Lung Identifies A Stage 1A Neuroendocrine Tumor in the Patient's Lung After PET Scan, Bronchoscopies and A Ser Serum Markers

bioAffinity Technologies, Inc. Releases New Case Study of A Complex Clinical Case in Which CyPath Lung Identifies Stage 1A Adenocarcinoma Lung Cancer in A Patient

bioAffinity Technologies Receives Non-Compliance Letter from Nasdaq Regarding Minimum Stockholders' Equity Requirement

bioAffinity Technologies, Inc. has filed a Follow-on Equity Offering in the amount of $5.801 million.

First quarter 2025 earnings: EPS in line with expectations, revenues disappoint

bioAffinity Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $3.233401 million.

bioAffinity Technologies, Inc. has filed a Follow-on Equity Offering in the amount of $11.123 million.

bioAffinity Technologies, Inc. Increases Efficiency of CyPath®? Lung Test by Boosting Data Acquisition Throughput by 50% and Reducing Unit Cost

bioAffinity Technologies, Inc. Announces Stuart Diamond Declines Re-Election as Member of the Board of Directors

bioAffinity Technologies, Inc. Provides Revenue Guidance for the Year 2025

Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

bioAffinity Technologies’ CyPath® Lung Detects Second Primary Lung Cancer in Patient With History of Lung Cancer

bioAffinity Technologies, Inc.'s Positive CyPath Lung Result Leads to Detecting Breast Cancer Recurrence

New major risk - Share price stability

New major risk - Market cap size

bioAffinity Technologies Receives Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price Requirement

New major risk - Market cap size

New major risk - Shareholder dilution

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

bioAffinity Technologies, Inc. Announces Executive Changes

bioAffinity Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $2.662782 million.

bioAffinity Technologies, Inc. has filed a Follow-on Equity Offering in the amount of $2.662782 million.

bioAffinity Technologies, Inc. Appoints J. Michael Edwards as Chief Financial Officer

New major risk - Share price stability

bioAffinity Technologies, Inc. Announces Chief Financial Officer Changes

New major risk - Shareholder dilution

New major risk - Revenue and earnings growth

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

bioAffinity Technologies, Inc. announced that it has received $1.302084 million in funding

bioAffinity Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $0.45 million.

bioAffinity Technologies, Inc. has filed a Follow-on Equity Offering in the amount of $0.45 million.

New major risk - Share price stability

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: US$0.20 loss per share (vs US$0.18 loss in 1Q 2023)